These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 29952526)

  • 1. The adaptive bacterial immune system CRISPR-Cas and its therapeutic potential.
    Tetsch L
    Med Monatsschr Pharm; 2017 Jan; 40(1):17-23. PubMed ID: 29952526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR/Cas9 Immune System as a Tool for Genome Engineering.
    Hryhorowicz M; Lipiński D; Zeyland J; Słomski R
    Arch Immunol Ther Exp (Warsz); 2017 Jun; 65(3):233-240. PubMed ID: 27699445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The application of CRISPR-Cas9 gene editing technology in viral infection diseases].
    Yin LJ; Hu SQ; Guo F
    Yi Chuan; 2015 May; 37(5):412-8. PubMed ID: 25998428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survey of clustered regularly interspaced short palindromic repeats and their associated Cas proteins (CRISPR/Cas) systems in multiple sequenced strains of Klebsiella pneumoniae.
    Ostria-Hernández ML; Sánchez-Vallejo CJ; Ibarra JA; Castro-Escarpulli G
    BMC Res Notes; 2015 Aug; 8():332. PubMed ID: 26238567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacterial CRISPR/Cas DNA endonucleases: A revolutionary technology that could dramatically impact viral research and treatment.
    Kennedy EM; Cullen BR
    Virology; 2015 May; 479-480():213-20. PubMed ID: 25759096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in Cas9 Enhance the Rate of Acquisition of Viral Spacer Sequences during the CRISPR-Cas Immune Response.
    Heler R; Wright AV; Vucelja M; Bikard D; Doudna JA; Marraffini LA
    Mol Cell; 2017 Jan; 65(1):168-175. PubMed ID: 28017588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR-Cas systems exploit viral DNA injection to establish and maintain adaptive immunity.
    Modell JW; Jiang W; Marraffini LA
    Nature; 2017 Apr; 544(7648):101-104. PubMed ID: 28355179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of CRISPR/Cas9 genome editing to the study and treatment of disease.
    Pellagatti A; Dolatshad H; Valletta S; Boultwood J
    Arch Toxicol; 2015 Jul; 89(7):1023-34. PubMed ID: 25827103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Editing of the Bacillus subtilis Genome by the CRISPR-Cas9 System.
    Altenbuchner J
    Appl Environ Microbiol; 2016 Sep; 82(17):5421-7. PubMed ID: 27342565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR-Cas: From the Bacterial Adaptive Immune System to a Versatile Tool for Genome Engineering.
    Kirchner M; Schneider S
    Angew Chem Int Ed Engl; 2015 Nov; 54(46):13508-14. PubMed ID: 26382836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR/Cas9 for genome editing: progress, implications and challenges.
    Zhang F; Wen Y; Guo X
    Hum Mol Genet; 2014 Sep; 23(R1):R40-6. PubMed ID: 24651067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruptive non-disruptive applications of CRISPR/Cas9.
    Schmid-Burgk JL
    Curr Opin Biotechnol; 2017 Dec; 48():203-209. PubMed ID: 28633080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in therapeutic CRISPR/Cas9 genome editing.
    Savić N; Schwank G
    Transl Res; 2016 Feb; 168():15-21. PubMed ID: 26470680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Harnessing CRISPR-Cas systems for bacterial genome editing.
    Selle K; Barrangou R
    Trends Microbiol; 2015 Apr; 23(4):225-32. PubMed ID: 25698413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional Analysis of Porphyromonas gingivalis W83 CRISPR-Cas Systems.
    Burmistrz M; Dudek B; Staniec D; Rodriguez Martinez JI; Bochtler M; Potempa J; Pyrc K
    J Bacteriol; 2015 Aug; 197(16):2631-41. PubMed ID: 26013482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR-Cas: biology, mechanisms and relevance.
    Hille F; Charpentier E
    Philos Trans R Soc Lond B Biol Sci; 2016 Nov; 371(1707):. PubMed ID: 27672148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutagenesis and Genome Engineering of Epstein-Barr Virus in Cultured Human Cells by CRISPR/Cas9.
    Yuen KS; Chan CP; Kok KH; Jin DY
    Methods Mol Biol; 2017; 1498():23-31. PubMed ID: 27709566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA-dependent DNA endonuclease Cas9 of the CRISPR system: Holy Grail of genome editing?
    Gasiunas G; Siksnys V
    Trends Microbiol; 2013 Nov; 21(11):562-7. PubMed ID: 24095303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cas9 specifies functional viral targets during CRISPR-Cas adaptation.
    Heler R; Samai P; Modell JW; Weiner C; Goldberg GW; Bikard D; Marraffini LA
    Nature; 2015 Mar; 519(7542):199-202. PubMed ID: 25707807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [CRISPR-Cas system as molecular scissors for gene therapy].
    Heinz GA; Mashreghi MF
    Z Rheumatol; 2017 Feb; 76(1):46-49. PubMed ID: 28124743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.